期刊
PATHOLOGY & ONCOLOGY RESEARCH
卷 26, 期 3, 页码 1879-1892出版社
SPRINGER
DOI: 10.1007/s12253-019-00773-3
关键词
Targeted tumor therapy; NGR peptides; Tumor growth inhibition; Antiangiogenic effect; CD13; Metastasis
资金
- Horizon 2020 [642004] Funding Source: Medline
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal [K116295, NKFIH K119552] Funding Source: Medline
- South Carolina Center of Economic Excellence (US) [1783-3/2018/FEKUTSRAT] Funding Source: Medline
- The 2019 Thematic Excellence Program [TUDFO/51757/2019-ITM] Funding Source: Medline
- European Union and the State of Hungary, co-financed by the European Regional Development Fund [VEKOP-2.3.3-15-2017-00020] Funding Source: Medline
- Nemzeti Kutatási és Technológiai Hivatal [NVKP_16-1-2016-0036] Funding Source: Medline
Among various homing devices, peptides containing the NGR tripeptide sequence represent a promising approach to selectively recognize CD13 receptor isoforms on the surface of tumor cells. They have been successfully used for the delivery of various chemotherapeutic drugs to tumor vessels. Here, we report on the murine plasma stability, in vitro andin vivoantitumor activity of our recently described bioconjugates containing daunorubicin as payload. Furthermore, CD13 expression of KS Kaposi's Sarcoma cell line and HT-29 human colon carcinoma cell line was investigated. Flow cytometry studies confirm the fast cellular uptake resulting in the rapid delivery of the active metabolite Dau = Aoa-Gly-OH to tumor cells. The increased in vitro antitumor effect might be explained by the faster rearrangement from NGR toisoDGR in case of conjugate2(Dau = Aoa-GFLGK(c[NleNGRE]-GG)-NH2) in comparison with conjugate1(Dau = Aoa-GFLGK(c[KNGRE]-GG)-NH2). Nevertheless, results indicated that both conjugates showed significant effect on inhibition of proliferation in the primary tumor and also on blood vessel formation making them a potential candidate for targeting angiogenesis processes in tumors where CD13 and integrins are involved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据